| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRNA | Common Stock | Options Exercise | $54.5K | +5K | +0.31% | $10.90* | 1.61M | Jul 23, 2021 | Direct | F1 |
| transaction | MRNA | Common Stock | Options Exercise | $9.9K | +10K | +0.62% | $0.99* | 1.62M | Jul 23, 2021 | Direct | F1 |
| transaction | MRNA | Common Stock | Sale | -$32.8K | -100 | -0.01% | $327.96 | 1.62M | Jul 23, 2021 | Direct | F1 |
| transaction | MRNA | Common Stock | Sale | -$132K | -400 | -0.02% | $329.91 | 1.62M | Jul 23, 2021 | Direct | F1, F2 |
| transaction | MRNA | Common Stock | Sale | -$1.95M | -5.9K | -0.36% | $330.96 | 1.62M | Jul 23, 2021 | Direct | F1, F3 |
| transaction | MRNA | Common Stock | Sale | -$443K | -1.33K | -0.08% | $332.15 | 1.62M | Jul 23, 2021 | Direct | F1, F4 |
| transaction | MRNA | Common Stock | Sale | -$401K | -1.2K | -0.07% | $334.14 | 1.62M | Jul 23, 2021 | Direct | F1, F5 |
| transaction | MRNA | Common Stock | Sale | -$268K | -800 | -0.05% | $335.36 | 1.61M | Jul 23, 2021 | Direct | F1, F6 |
| transaction | MRNA | Common Stock | Sale | -$202K | -600 | -0.04% | $336.81 | 1.61M | Jul 23, 2021 | Direct | F1, F7 |
| transaction | MRNA | Common Stock | Sale | -$451K | -1.33K | -0.08% | $338.07 | 1.61M | Jul 23, 2021 | Direct | F1, F8 |
| transaction | MRNA | Common Stock | Sale | -$289K | -854 | -0.05% | $338.90 | 1.61M | Jul 23, 2021 | Direct | F1, F9 |
| transaction | MRNA | Common Stock | Sale | -$102K | -300 | -0.02% | $340.65 | 1.61M | Jul 23, 2021 | Direct | F1, F10 |
| transaction | MRNA | Common Stock | Sale | -$102K | -297 | -0.02% | $341.98 | 1.61M | Jul 23, 2021 | Direct | F1, F11 |
| transaction | MRNA | Common Stock | Sale | -$137K | -400 | -0.02% | $342.76 | 1.61M | Jul 23, 2021 | Direct | F1, F12 |
| transaction | MRNA | Common Stock | Sale | -$139K | -401 | -0.02% | $345.51 | 1.61M | Jul 23, 2021 | Direct | F1, F13 |
| transaction | MRNA | Common Stock | Sale | -$139K | -400 | -0.02% | $346.52 | 1.61M | Jul 23, 2021 | Direct | F1, F14 |
| transaction | MRNA | Common Stock | Sale | -$165K | -474 | -0.03% | $347.83 | 1.61M | Jul 23, 2021 | Direct | F1, F15 |
| transaction | MRNA | Common Stock | Sale | -$72.5K | -208 | -0.01% | $348.41 | 1.61M | Jul 23, 2021 | Direct | F1, F16 |
| transaction | MRNA | Common Stock | Options Exercise | $54.5K | +5K | +0.31% | $10.90* | 1.61M | Jul 26, 2021 | Direct | F1 |
| transaction | MRNA | Common Stock | Sale | -$1.76M | -5K | -0.31% | $351.99 | 1.61M | Jul 26, 2021 | Direct | F1 |
| holding | MRNA | Common Stock | 4.12K | Jul 23, 2021 | By Valhalla, LLC | ||||||
| holding | MRNA | Common Stock | 152K | Jul 23, 2021 | By Trust | F17 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRNA | Stock Option (Right to Buy) | Options Exercise | $0 | -5K | -1.81% | $0.00 | 272K | Jul 23, 2021 | Common Stock | 5K | $10.90 | Direct | F1, F18 |
| transaction | MRNA | Stock Option (Right to Buy) | Options Exercise | $0 | -10K | -2.45% | $0.00 | 397K | Jul 23, 2021 | Common Stock | 10K | $0.99 | Direct | F1, F19 |
| transaction | MRNA | Stock Option (Right to Buy) | Options Exercise | $0 | -5K | -1.84% | $0.00 | 267K | Jul 26, 2021 | Common Stock | 5K | $10.90 | Direct | F1, F18 |
| Id | Content |
|---|---|
| F1 | The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $329.40 to $330.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F3 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $330.75 to $331.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F4 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $331.78 to $332.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F5 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $333.75 to $334.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F6 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $334.83 to $335.82. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F7 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $336.40 to $337.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F8 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $337.50 to $338.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F9 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $338.59 to $339.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F10 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $340.16 to $341.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F11 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $341.40 to $342.36. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F12 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $342.48 to $343.43. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F13 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $344.93 to $345.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F14 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $346.14 to $346.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F15 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $347.20 to $348.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F16 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $348.24 to $348.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F17 | These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
| F18 | 25% of this option vested and became exercisable on February 23, 2017, with the remainder vesting in 12 equal quarterly installments thereafter. |
| F19 | This option is fully vested and exercisable. |